R. Neubauer

Pilot Study of Organ Preservation Multimodality Therapy for Locally Advanced Resectable Oropharyngeal Carcinoma

R. Weber, A. Chalian, D. Rosenthal, 2000, American journal of clinical oncology.

SAT0328 An open-label study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis

R. Neubauer, A. Schorpion, M. Shenin, 2017 .

Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial

M. Uder, A. Cremer, P. Gosse, 2021, The Lancet.

A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis

R. Neubauer, C. Derk, A. Schorpion, 2018, BMC Rheumatology.

Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.

D. Brennan, R. Bloom, R. Neubauer, 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.

D. Brennan, R. Bloom, R. Neubauer, 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.